Stock Price Quote

BLISS GVS PHARMA LTD.

NSE : BLISSGVSBSE : 506197ISIN CODE : INE416D01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE112.65-1.5 (-1.31 %)
PREV CLOSE ( ) 114.15
OPEN PRICE ( ) 115.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 39688
TODAY'S LOW / HIGH ( )112.00 116.35
52 WK LOW / HIGH ( )69.15 148.95
NSE112.85-1.2 (-1.05 %)
PREV CLOSE( ) 114.05
OPEN PRICE ( ) 115.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 112.85 (5478)
VOLUME 367160
TODAY'S LOW / HIGH( ) 111.55 116.70
52 WK LOW / HIGH ( )69.2 149.6
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984
Management Info
S R Vaidya - Chairman Gagan Harsh Sharma - Managing Director
Registered Office

Address 102, Hyde Park,Saki Vihar Road,Andheri (East) ,
Mumbai,
Maharashtra-400072

Phone 022-42160000 / 28505387

Email info@blissgvs.com

Website www.blissgvs.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Road,Vikhroli West,Mumbai
Listing : BSE, NSE, MCX

NEWS

15Jan Announcement under Regulation 30 (LOD
We would like to inform you that, the ESOP Allotment Committee of the Co..
19Jul Bliss Gvs Pharma informs about AGM out
Bliss Gvs Pharma has informed that it enclosed proceedings of the 38th A..
15Jun Bliss GVS Pharma gets EIR for Palghar
Bliss GVS Pharma has received the Establishment Inspection Report (EIR)..
12May Bliss Gvs Pharma informs about book cl
Bliss Gvs Pharma has informed that the Register of Members and Share Tra..
20Mar USFDA conducts inspections at Bliss GV
United States Food and Drug Administration (USFDA) has conducted a Pre-A..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit207.19854.77
Gross Profit 285.2 1156.91
Operating Profit 365.561409.21
Net Sales 1613.355983.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26946.00 (0.74%)
M.Cap ( in Cr)57258.37
Sanofi India (BSE)
peergroup  8118.25 (2.06%)
M.Cap ( in Cr)18696.83
Dr. Reddy's Lab (BSE)
peergroup  6155.15 (1.78%)
M.Cap ( in Cr)102679.14
Divi's Lab (BSE)
peergroup  3436.75 (2.14%)
M.Cap ( in Cr)91234.91
Glaxosmithkline Phar (BSE)
peergroup  1943.10 (3.26%)
M.Cap ( in Cr)32917.29

Shareholding Pattern

FI/BANKS/INSURANCE 6.59%
NON-INSTITUTION 43.08%
PROMOTERS 34.97%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%

About Bliss GVS Pharma Ltd.

Bliss GVS Pharma Ltd. was incorporated in the year 1984. Its today's share price is 112.65. Its current market capitalisation stands at Rs 1179.34 Cr. In the latest quarter, company has reported Gross Sales of Rs. 5983.4 Cr and Total Income of Rs.6491.06 Cr. The company's management includes Aditi Bhatt, Shruti Vishal Rao, Shilpa Bhatia, Gagan Harsh Sharma, Vibha Gagan Sharma, Santosh Parab, S R Vaidya.

It is listed on the BSE with a BSE Code of 506197 , NSE with an NSE Symbol of BLISSGVS and ISIN of INE416D01022. It's Registered office is at 102, Hyde Park,Saki Vihar Road,Andheri (East) Mumbai-400072, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BK Khare & Co, Kalyaniwalla & Mistry LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.